NovoCure (NVCR) Projected to Post Quarterly Earnings on Thursday

NovoCure (NASDAQ:NVCR) is expected to be releasing its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect NovoCure to post earnings of ($0.40) per share and revenue of $174.3980 million for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:00 AM ET.

NovoCure Price Performance

NovoCure stock opened at $11.74 on Wednesday. The business has a fifty day moving average price of $12.64 and a 200-day moving average price of $12.61. The firm has a market capitalization of $1.31 billion, a P/E ratio of -7.29 and a beta of 0.73. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.55 and a quick ratio of 1.50. NovoCure has a one year low of $9.82 and a one year high of $22.30.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Corient Private Wealth LLC raised its holdings in shares of NovoCure by 178.0% in the fourth quarter. Corient Private Wealth LLC now owns 97,368 shares of the medical equipment provider’s stock valued at $1,259,000 after buying an additional 62,341 shares during the last quarter. Mercer Global Advisors Inc. ADV increased its position in NovoCure by 14.5% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 32,660 shares of the medical equipment provider’s stock valued at $422,000 after acquiring an additional 4,124 shares during the period. Empowered Funds LLC purchased a new stake in NovoCure during the 4th quarter valued at approximately $33,000. XTX Topco Ltd lifted its position in NovoCure by 159.2% during the 4th quarter. XTX Topco Ltd now owns 58,795 shares of the medical equipment provider’s stock worth $760,000 after acquiring an additional 36,111 shares during the period. Finally, Vestal Point Capital LP grew its stake in shares of NovoCure by 31.3% in the 4th quarter. Vestal Point Capital LP now owns 525,000 shares of the medical equipment provider’s stock valued at $6,788,000 after purchasing an additional 125,000 shares during the last quarter. 84.61% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on NVCR. Weiss Ratings restated a “sell (e+)” rating on shares of NovoCure in a research report on Thursday, January 22nd. Evercore set a $20.00 price objective on shares of NovoCure in a research report on Monday, January 5th. HC Wainwright increased their target price on NovoCure from $39.00 to $47.00 and gave the company a “buy” rating in a research note on Thursday, February 12th. Finally, Wedbush reissued a “neutral” rating and set a $18.00 price target on shares of NovoCure in a research note on Thursday, January 15th. Three equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $26.64.

About NovoCure

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.